황반변성 치료 시장 규모는 향후 몇 년동안 빠르게 성장할 것으로 예상되며, 2029년까지 11.3%의 연평균 복합 성장률(CAGR)로 190억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 연구 발전, 의료비 지출 증가, 이환율 증가, 개인 맞춤형 의료 접근법, 시력 건강에 대한 전 세계의 노력에 기인합니다. 예측 기간 동안 주요 동향으로는 신경 보호 및 재생 치료에 대한 집중, 원격 의료 및 원격 모니터링의 확대, 개인 맞춤형 의료 접근법, 줄기세포 치료 연구, 환자 중심의 인식 개선 및 교육 이니셔티브 등이 있습니다.
망막 질환 증가는 황반변성 치료 시장의 성장을 견인할 것으로 예상됩니다. 망막 장애는 중요한 조직에 영향을 미쳐 시각 정보 처리를 방해하고 왜곡된 시력 및 장애를 초래할 수 있습니다. 미국 안과학회(American Academy of Ophthalmology)에 따르면, 2050년까지 미국에서 약 732만 명이 원발성 개방각 녹내장을 앓을 것으로 예상됩니다. 이 질환은 70-79세(32%), 여성(50%), 히스패닉계(50%)에서 가장 많이 발병할 것으로 예상됩니다. 히스패닉계 남성이 가장 많습니다. 결과적으로 망막질환의 유병률 증가는 황반변성 치료 시장 확대에 박차를 가하고 있습니다.
고령화 인구 증가는 향후 황반변성 치료 시장의 성장을 견인할 것으로 예상됩니다. 고령화란 사회나 인구에서 노인의 비율이 높아지는 것을 특징으로 하는 인구 통계학적 변화를 말합니다. 황반변성 치료는 고령화 사회의 시력 장애를 목표로 하고 있으며, 망막 중심부에 영향을 미치는 질환에 초점을 맞추었습니다. 예를 들어, 2022년 10월 세계보건기구(WHO)는 2030년까지 전 세계 인구 6명 중 1명이 60세 이상이 될 것으로 예측했습니다. 이 기간 동안 60세 이상 인구 비율은 2020년 10억 명에서 14억 명으로 증가할 것으로 예상됩니다. 또한, 전 세계 60세 이상 인구는 두 배로 증가하여 2050년에는 21억 명에 달할 것으로 예상됩니다. 따라서 고령화 인구 증가는 황반변성 치료 시장을 견인하는 중요한 요인이 되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계황반변성치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
- 최종 이용 산업 분석
- 세계의 황반변성 치료 시장 : 성장률 분석
- 세계의 황반변성 치료 시장 실적 : 규모와 성장, 2019-2024
- 세계의 황반변성 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계황반변성치료 전체 시장(TAM)
제6장 시장 세분화
- 세계의 황반변성 치료 시장 : 질병 진행도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 초기 AMD
- 중기 AMD
- 말기 AMD
- 세계의 황반변성 치료 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 외래수술센터(ASC)
- 안과 클리닉
- 병원
- 세계의 황반변성 치료 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 주사
- 기타 투여 경로
- 세계의 황반변성 치료 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 습성 황반변성
- 건성 황반변성
- 세계의 황반변성 치료 시장 : 초기 AMD 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 영양 보충제
- 생활습관 교정 치료
- 세계의 황반변성 치료 시장 : 중기 AMD 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 항VEGF 주사
- 광선 역학 요법
- 세계의 황반변성 치료 시장 : 말기 AMD 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 외과적 치료
- 첨단 항VEGF 요법
- 유전자 치료 옵션
제7장 지역별/국가별 분석
- 세계의 황반변성 치료 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 황반변성 치료 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 황반변성 치료 시장 : 경쟁 구도
- 황반변성 치료 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
- GlaxoSmithKline plc
- Panoptica
- Regeneron Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Santen Pharmaceuticals
- Aerie Pharmaceuticals Inc.
- BioXcel Therapeutics Inc.
- Regenxbio Inc.
- Spark Therapeutics Inc.
- Alimera Sciences Inc.
- Applied Genetic Technologies Corp(AGTC)
- Cell Medica Ltd.
- Ophthotech Corporation
- Adverum Biotechnologies Inc.
- Neurotech Pharmaceuticals Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 황반변성 치료 시장(2029년) : 새로운 기회를 제공하는 국가
- 황반변성 치료 시장(2029년) : 새로운 기회를 제공하는 부문
- 황반변성 치료 시장(2029년) : 성장 전략
제36장 부록
LSH
The macula is the central part of the retina responsible for central vision. Age-related macular degeneration (AMD) is a common condition in individuals over 60, resulting in the degeneration of the macula and causing distortion or loss of central vision. Treatment aims to slow the progression of the disease and prevent severe vision loss.
The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. Early-stage AMD is characterized by changes in the macula with medium-sized drusen deposits and no impact on vision. Intermediate AMD may cause blurry or wavy vision due to large drusen or pigment changes. Late-stage AMD results in complete central vision loss. Macular degeneration treatments include wet and dry types, administered orally, via injection, or other methods. These treatments are utilized in various medical settings such as ambulatory surgical centers, ophthalmic clinics, and hospitals.
The macular degeneration treatment research report is one of a series of new reports from The Business Research Company that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $11.05 billion in 2024 to $12.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to aging population, lifestyle changes, limited treatment options, rising awareness, healthcare infrastructure development.
The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $19.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, global efforts for vision health. Major trends in the forecast period include focus on neuroprotection and regeneration therapies, expansion of telemedicine and remote monitoring, personalized medicine approaches, investigation of stem cell therapies, patient-focused initiatives for awareness and education.
The rise in retinal disorders is anticipated to drive the growth of the macular degeneration treatment market. Retinal disorders impact critical tissue and can disrupt the processing of visual information, resulting in distorted or impaired vision. According to the American Academy of Ophthalmology, by 2050, approximately 7.32 million people in the United States are projected to be affected by primary open-angle glaucoma, a collective term for a group of eye conditions. This condition is expected to be most prevalent among individuals aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Consequently, the escalating prevalence of retinal disorders is fueling the expansion of the macular degeneration treatment market.
The increasing aging population is expected to drive the growth of the macular degeneration treatment market in the future. An aging population refers to a demographic shift characterized by a higher proportion of elderly individuals within a society or population. Macular degeneration treatment targets vision impairment in the aging population, focusing on a condition that affects the central part of the retina. For example, in October 2022, the World Health Organization projected that by 2030, 1 out of every 6 individuals globally would be 60 years old or older. During this period, the proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Therefore, the increasing aging population is a key factor driving the macular degeneration treatment market.
Major companies in the macular degeneration treatment market are concentrating on the development of biosimilars for age-related macular degeneration (AMD) to enhance access to effective therapies. Biosimilars are biological medical products that are highly comparable to an already approved reference product, demonstrating no clinically meaningful differences in safety, purity, or potency. For example, in May 2024, Biocon Biologics Ltd, based in India, and Samsung Bioepis Co. Ltd, a South Korean company, received FDA approval for their two new biosimilars, Yesafili and Opuviz. Both biosimilars target vascular endothelial growth factor (VEGF), which is implicated in abnormal blood vessel growth in the eye, thus helping to prevent vision loss related to AMD and diabetic retinopathy. The FDA's approval process included comparative studies demonstrating that Yesafili and Opuviz have no significant differences in efficacy or safety compared to Eylea. These studies involved comprehensive assessments of the biosimilars' pharmacokinetics and immunogenicity.
Major players in the macular degeneration treatment market are focusing on innovative solutions, such as the avacincaptad pegol intravitreal solution developed for geographic atrophy, to enhance their market performance. This solution acts as a complement C5 inhibitor targeting geographic atrophy secondary to macular degeneration. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY, an avacincaptad pegol intravitreal solution designed for treating geographic atrophy (GA) linked to age-related macular degeneration (AMD). In two Phase 3 clinical trials, IZERVAY, as a complement C5 inhibitor, demonstrated a significant reduction in GA progression at the 12-month primary endpoint. Notably, the solution showed a decrease in photoreceptor loss within six months of treatment, highlighting its potential impact on addressing macular degeneration.
In July 2023, Harrow Inc., a US-based company, acquired Santen for $8 million. This acquisition is part of Harrow's strategy to enhance its portfolio by leveraging Santen's expertise in macular degeneration treatment. Santen Pharmaceutical Co., Ltd. is a Japan-based company specializing in treatments for macular degeneration.
Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.
North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Macular Degeneration Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on macular degeneration treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for macular degeneration treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The macular degeneration treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD
- 2) By End User: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals
- 3) By Route of Administration: Oral; Injectable; Other Route of Administration
- 4) By Types: Wet Macular Degeneration, Dry Macular Degeneration
- Subsegments:
- 1) By Early-Stage AMD: Nutritional Supplements; Lifestyle Modification Treatments
- 2) By Intermediate AMD: Anti-VEGF Injections; Photodynamic Therapy
- 3) By Late-Stage AMD: Surgical Treatments; Advanced Anti-VEGF Therapies; Gene Therapy Options
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Allergan Inc.; Bayer AG; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Macular Degeneration Treatment Market Characteristics
3. Macular Degeneration Treatment Market Trends And Strategies
4. Macular Degeneration Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Macular Degeneration Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Macular Degeneration Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Macular Degeneration Treatment Market Growth Rate Analysis
- 5.4. Global Macular Degeneration Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Macular Degeneration Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Macular Degeneration Treatment Total Addressable Market (TAM)
6. Macular Degeneration Treatment Market Segmentation
- 6.1. Global Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Early-Stage AMD
- Intermediate AMD
- Late-Stage AMD
- 6.2. Global Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ambulatory Surgical Centers
- Ophthalmic Clinics
- Hospitals
- 6.3. Global Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- Other Route of Administration
- 6.4. Global Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Wet Macular Degeneration
- Dry Macular Degeneration
- 6.5. Global Macular Degeneration Treatment Market, Sub-Segmentation Of Early-Stage AMD, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nutritional Supplements
- Lifestyle Modification Treatments
- 6.6. Global Macular Degeneration Treatment Market, Sub-Segmentation Of Intermediate AMD, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anti-VEGF Injections
- Photodynamic Therapy
- 6.7. Global Macular Degeneration Treatment Market, Sub-Segmentation Of Late-Stage AMD, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgical Treatments
- Advanced Anti-VEGF Therapies
- Gene Therapy Options
7. Macular Degeneration Treatment Market Regional And Country Analysis
- 7.1. Global Macular Degeneration Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Macular Degeneration Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Macular Degeneration Treatment Market
- 8.1. Asia-Pacific Macular Degeneration Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Macular Degeneration Treatment Market
- 9.1. China Macular Degeneration Treatment Market Overview
- 9.2. China Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Macular Degeneration Treatment Market
- 10.1. India Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Macular Degeneration Treatment Market
- 11.1. Japan Macular Degeneration Treatment Market Overview
- 11.2. Japan Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Macular Degeneration Treatment Market
- 12.1. Australia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Macular Degeneration Treatment Market
- 13.1. Indonesia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Macular Degeneration Treatment Market
- 14.1. South Korea Macular Degeneration Treatment Market Overview
- 14.2. South Korea Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Macular Degeneration Treatment Market
- 15.1. Western Europe Macular Degeneration Treatment Market Overview
- 15.2. Western Europe Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Macular Degeneration Treatment Market
- 16.1. UK Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Macular Degeneration Treatment Market
- 17.1. Germany Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Macular Degeneration Treatment Market
- 18.1. France Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Macular Degeneration Treatment Market
- 19.1. Italy Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Macular Degeneration Treatment Market
- 20.1. Spain Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Macular Degeneration Treatment Market
- 21.1. Eastern Europe Macular Degeneration Treatment Market Overview
- 21.2. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Macular Degeneration Treatment Market
- 22.1. Russia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Macular Degeneration Treatment Market
- 23.1. North America Macular Degeneration Treatment Market Overview
- 23.2. North America Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Macular Degeneration Treatment Market
- 24.1. USA Macular Degeneration Treatment Market Overview
- 24.2. USA Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Macular Degeneration Treatment Market
- 25.1. Canada Macular Degeneration Treatment Market Overview
- 25.2. Canada Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Macular Degeneration Treatment Market
- 26.1. South America Macular Degeneration Treatment Market Overview
- 26.2. South America Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Macular Degeneration Treatment Market
- 27.1. Brazil Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Macular Degeneration Treatment Market
- 28.1. Middle East Macular Degeneration Treatment Market Overview
- 28.2. Middle East Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Macular Degeneration Treatment Market
- 29.1. Africa Macular Degeneration Treatment Market Overview
- 29.2. Africa Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Macular Degeneration Treatment Market Competitive Landscape And Company Profiles
- 30.1. Macular Degeneration Treatment Market Competitive Landscape
- 30.2. Macular Degeneration Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Macular Degeneration Treatment Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. Panoptica
- 31.3. Regeneron Pharmaceuticals Inc.
- 31.4. Bausch Health Companies Inc.
- 31.5. Santen Pharmaceuticals
- 31.6. Aerie Pharmaceuticals Inc.
- 31.7. BioXcel Therapeutics Inc.
- 31.8. Regenxbio Inc.
- 31.9. Spark Therapeutics Inc.
- 31.10. Alimera Sciences Inc.
- 31.11. Applied Genetic Technologies Corp (AGTC)
- 31.12. Cell Medica Ltd.
- 31.13. Ophthotech Corporation
- 31.14. Adverum Biotechnologies Inc.
- 31.15. Neurotech Pharmaceuticals Inc.
32. Global Macular Degeneration Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Macular Degeneration Treatment Market
34. Recent Developments In The Macular Degeneration Treatment Market
35. Macular Degeneration Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Macular Degeneration Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Macular Degeneration Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Macular Degeneration Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
